GCGR and type 1 diabetes mellitus: In clinical studies, a single dose of REMD-477 (Volagidemab), a GCGR monoclonal antibody, significantly reduced insulin requirements in patients with T1DM and improved glycemic control, without inducing serious adverse effects [48].